AtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100
Debt
Debt-to-Equity Ratio0.34
Current Ratio3.15
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-33.63
Forward P/E Ratio-32.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$174.72 million
Price / Sales5.60
Cash FlowN/A
Price / CashN/A
Book Value$4.67 per share
Price / Book5.98
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-14.88%
Return on Equity-16.92%
Return on Assets-9.99%
Miscellaneous
Employees570
Outstanding Shares35,040,000
AtriCure (NASDAQ:ATRC) Frequently Asked Questions
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
How were AtriCure's earnings last quarter?
AtriCure Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Thursday, April, 26th. The medical device company reported ($0.31) EPS for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to the consensus estimate of $45.43 million. AtriCure had a negative net margin of 14.88% and a negative return on equity of 16.92%. The firm's revenue was up 13.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.32) EPS. View AtriCure's Earnings History.
When is AtriCure's next earnings date?
What price target have analysts set for ATRC?
4 Wall Street analysts have issued 12-month target prices for AtriCure's shares. Their predictions range from $23.00 to $32.00. On average, they anticipate AtriCure's share price to reach $26.25 in the next twelve months. View Analyst Ratings for AtriCure.
What are Wall Street analysts saying about AtriCure stock?
Here are some recent quotes from research analysts about AtriCure stock:
- 1. Needham & Company LLC analysts commented, "We have increased confidence in ATRC’s ability to sustain strong revenue growth and to drive upside to consensus estimates given: 1) strong Open-Heart Ablation growth driven by society guidelines and increasing penetration, 2) strong AtriClip growth driven by new products with higher prices, 3) conservative guidance, and 4) easing comps, particularly in 2H18. Additionally, we expect ATRC’s analyst meeting (6/26 in NYC) to serve as a nearer-term catalyst and results from its CONVERGE trial to serve a a significant longer-term catalyst in 2H19. Given this, we raise our price target to $32 from $26 and reiterate our Buy rating." (6/18/2018)
- 2. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/2/2018)
Who are some of AtriCure's key competitors?
Some companies that are related to AtriCure include Novocure (NVCR), NuVasive (NUVA), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Glaukos (GKOS), Mazor Robotics (MZOR), Luminex (LMNX), Intersect ENT (XENT), Orthofix International (OFIX), Atrion (ATRI), OraSure Technologies (OSUR), Cryolife (CRY), Cardiovascular Systems (CSII) and Tactile Systems Technology (TCMD).
Who are AtriCure's key executives?
AtriCure's management team includes the folowing people:
- Mr. Michael H. Carrel, CEO, Pres & Director (Age 47)
- Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 43)
- Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
- Mr. Salvatore Privitera, Chief Technology Officer (Age 51)
- Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 40)
Has AtriCure been receiving favorable news coverage?
News stories about ATRC stock have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a news impact score of 0.14 on Accern's scale. They also assigned media coverage about the medical device company an impact score of 46.91 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are AtriCure's major shareholders?
AtriCure's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.48%), Hudson Executive Capital LP (6.78%), First Light Asset Management LLC (3.33%), Millennium Management LLC (2.45%), Loomis Sayles & Co. L P (2.30%) and Neuberger Berman Group LLC (2.23%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar and Regina E Groves. View Institutional Ownership Trends for AtriCure.
Which institutional investors are selling AtriCure stock?
ATRC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc., GSA Capital Partners LLP, Neuberger Berman Group LLC, Wasatch Advisors Inc., Loomis Sayles & Co. L P, Nuveen Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Mark A Collar. View Insider Buying and Selling for AtriCure.
Which institutional investors are buying AtriCure stock?
ATRC stock was acquired by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, The Manufacturers Life Insurance Company , Millennium Management LLC, First Light Asset Management LLC, Quantum Capital Management, Tamarack Advisers LP, Trexquant Investment LP and Highbridge Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.
How do I buy shares of AtriCure?
Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AtriCure's stock price today?
One share of ATRC stock can currently be purchased for approximately $27.91.
How big of a company is AtriCure?
AtriCure has a market capitalization of $1.00 billion and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.
How can I contact AtriCure?
AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.
MarketBeat Community Rating for AtriCure (ATRC)
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
